Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linperlisib plus adebrelimab as second-line treatment for advanced biliary tract cancer
ChiCTR2400085148Phase 4Recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of linperlisib and adebrelimab in biliary cancer, sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoints: Dose-limiting toxicity and Overall response rate. Started May 2024; status: recruiting.
02
Drugs
linperlisibadebrelimab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2400085148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085148.